title: [Individually Safe and Realistic Correction of Antipsychotic Polypharmacy and High-dose Regimens in Japanese Patients with Chronic Schizophrenia: The SCAP method].
abstract: Compared with other countries, Japan exhibits prominent levels of antipsychotic polypharmacy and high-dose regimens. In view of these circumstances, the Safe Correction of Antipsychotic Polypharmacy and high-dose regimens (SCAP) method was developed based on previous findings as a realistic way to reduce medication consumption in patients already experiencing polypharmacy and high-dose regimens. In the SCAP method, "clinicians can reduce medications one by one, gradually, with occasional breaks permitted." A clinical study conducted to evaluate this method found no change in clinical symptoms, side effects, or quality of life (QOL), and the number of withdrawals due to aggravation was also small. A leaflet describing these results, and which is designed to support efforts to reduce medications, has been released. Future research will involve the examination and analysis of data from this study, taking into account its limitations, with a view toward developing guidelines applicable to clinical settings. The pragmatic, gradual correction of polypharmacy and high-dose regimens that goes beyond the "multiple drugs or single agent" dichotomy can decrease the burden experienced by patients. This is a practical approach that can be applied when developing comprehensive plans for the future psychiatric care of aging patient populations.
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Yamanouchi
authors.forename: Tsuruhei
authors.initials: T
authors.lastname: Sukegawa
authors.forename: Ataru
authors.initials: A
authors.lastname: Inagaki
authors.forename: Toshiya
authors.initials: T
authors.lastname: Inada
authors.forename: Takashi
authors.initials: T
authors.lastname: Yoshio
authors.forename: Reiji
authors.initials: R
authors.lastname: Yoshimura
authors.forename: Nakao
authors.initials: N
authors.lastname: Iwata
mesh_terms: D000375:Aging; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D044466:Asian People; D002908:Chronic Disease; D006801:Humans; D019338:Polypharmacy; D011788:Quality of Life; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents